Intravenous Fluorouracil versus Oral Capecitabine: Postoperative Chemoradiation for Gastric Cancer


Purpose: Aim of this prospective, phase III trial was to compare the efficacy and toxicity of intravenous fluorouracil and oral capecitabine when given concurrently with radiation in adjuvant sitting for adenocarcinoma of the stomach after gastrectomy with D2 resection. Patients and Method: The study included 60 patients having histologically proven adenocarcinoma of the stomach or gastroesophageal junction; stage T2-4 N0-3 M0 after gastrectomy with D2 lymph node dissection. Eligible patients were randomly assigned to receive adjuvant radiotherapy concurrently with intravenous fluorouracil [arm A] or oral capecitabine [arm B]. Results: Ten patients cannot complete their whole treatment course because of either progressive [4 patients; 2 arm A and 2 arm B] or G 3 toxicity [1 patient] or refuse to complete their treatment [5 patients; 3 arm A and 2 arm B]. Patients received fluorouracil have significant increase grade 3 or 4 hematological [neutropenia] and gastrointestinal (diarrhoea, anorexia, and vomiting). During a median follow-up period of 24 months, the 2-year disease free and overall survivals in this study were 60% and 63.3%, for groups A and B respectively, while overall survival were 63.3% and 70% for groups A and B respectively without significant differences. Conclusion: Oral capecitabine concurrently with radiation therapy has comparable efficacy and favourable toxicity profile when compared to infusion fluorouracil as postoperative adjuvant therapy for gastric adenocarcinoma.

Share and Cite:

Abbas, H. , Ahmed, S. , Salem, A. , Salem, M. , Hussin, M. and Sherief, W. (2015) Intravenous Fluorouracil versus Oral Capecitabine: Postoperative Chemoradiation for Gastric Cancer. Journal of Cancer Therapy, 6, 954-962. doi: 10.4236/jct.2015.611103.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Tham, C.K., Choo, S.P., Poon, D.Y.H., Toh, H.C., Ong, S.Y.K., Tan, S.H., Wang, M.L.C. and Foo, K.F. (2010) Capecitabine with Radiation is an Effective Adjuvant Therapy in Gastric Cancers. World Journal of Gastroenterology, 16, 3709-3715.
[2] Cunningham, D., Allum, W.H., Stenning, S.P., et al. (2006) Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. The New England Journal of Medicine, 355, 11-20.
[3] Bajetta, E., Buzzoni, R., Mariani, L., Beretta, E., Bozzetti, F., Bordogna, G., Aitini, E., Fava, S., Schieppati, G., Pinotti, G., Visini, M., Ianniello, G. and Di, B.M. (2002) Adjuvant Chemotherapy in Gastric Cancer: 5-Year Results of a Randomised Study by the Italian Trials in Medical Oncology (ITMO) Group. Annals of Oncology, 13, 299-307.
[4] Allum, W.H., Hallissey, M.T., Ward, L.C. and Hocke, M.S., British Stomach Cancer Group (1989) A Controlled, Prospective, Randomised Trial of Adjuvant Chemotherapy or Radiotherapy in Resectable Gastric Cancer: Interim Report. British Journal of Cancer, 60, 739-744.
[5] Macdonald, J.S., Smalley, S.R., Benedetti, J., et al. (2001) Chemoradiotherapy after Surgery Compared with Surgery alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction. The New England Journal of Medicine, 345, 725-730.
[6] Macdonald, J.S., Benedetti, J., Smalley, S., et al. (2009) Chemoradiation of Resected Gastric Cancer: A 10-Year Follow up of the Phase III Trial INT 0116 (SWOG 9008). Journal of Clinical Oncology, 27, 15s. (Suppl; abstr 4515).
[7] Wagner, A.D., Grothe, W., Haerting, J., et al. (2006) Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data. Journal of Clinical Oncology, 24, 2903-2909.
[8] Meyerhardt, J.A. and Mayer, R.J. (2005) Systemic Therapy for Colorectal Cancer. The New England Journal of Medicine, 352, 476-487.
[9] Cunningham, D., Rao, S., Starling, N., et al. (2006) Randomised Multicentre Phase III Study Comparing Capecitabine with Fluorouracil and Xaliplatin with Cisplatin in Patients with Advanced Oesophagogastric Cancer: The REAL 2 Trial. Journal of Clinical Oncology, 24, 18S.
[10] Jansen, E.P., Boot, H., Saunders, M.P., Crosby, T.D., Dubbelman, R., Bartelink, H., Verheij, M. and Cats, A. (2007) A Phase I-II Study of Postoperative Capecitabine-Based Chemoradiotherapy in Gastric Cancer. International Journal of Radiation Oncology, Biology, Physics, 69, 1424-1428.
[11] Schuller, J., Cassidy, J., Dumont, E., Roos, B., Durston, S., Banken, L., Utoh, M., Mori, K., Weidekamm, E. and Reigner, B. (2000) Preferential Activation of Capecitabine in Tumor Following Oral Administration to Colorectal Cancer Patients. Cancer Chemotherapy and Pharmacology, 45, 291-297.
[12] Kang, Y.K., Kang, W.K., Shin, D.B., Chen, J., Xiong, J., Wang, J., Lichinitser, M., Guan, Z., Khasanov, R., Zheng, L., Philco-Salas, M., Suarez, T., Santamaria, J., Forster, G. and McCloud, P.I. (2009) Capecitabine/Cisplatin versus 5-Fluorouracil/Cisplatin as First-Line Therapy in Patients with Advanced Gastric Cancer: A Randomized Phase III Noninferiority Trial. Annals of Oncology, 20, 666-673.
[13] Bosset, J.F., Collette, L., Calais, G., et al. (2006) Chemotherapy with Preoperative Radiotherapy in Rectal Cancer. New England Journal of Medicine, 355, 1114-1123.
[14] Rodel, C., Grabenbauer, G.G., Papadopoulos, T., et al. (2003) Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer. Journal of Clinical Oncology, 21, 3098-3104.
[15] Lee, H.S., Choi, Y., Hur, W.J., Kim, H.J., Kwon, H.C., Kim, S.H., Kim, J.S., Lee, J.H., Jung, G.J. and Kim, M.C. (2006) Pilot Study of Postoperative Adjuvant Chemoradiation for Advanced Gastric Cancer: Adjuvant 5-FU/Cisplatin and Chemoradiation with Capecitabine. World Journal of Gastroenterology, 12, 603-607.
[16] Tham, C.K., Choo, S.P., Poon, D.Y., Toh, H.C., Ong, S.Y., Tan, S.H., et al. (2010) Capecitabine with Radiation Is an Effective Adjuvant Therapy in Gastric Cancers. World Journal of Gastroenterology, 16, 3709-3715.
[17] Hartgrink, H.H., van de Velde, C.J., Putter, H., et al. (2004) Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial. Journal of Clinical Oncology, 22, 2069-2077.
[18] Lim, D.H., Kim, D.Y., Kang, M.K., Kim, Y.I., Kang, W.K., Park, C.K., Kim, S., Noh, J.H., Joh, J.W., Choi, S.H., Sohn, T.S., Heo, J.S., Park, C.H., Park, J.O., Lee, J.E., Park, Y.J., Nam, H.R., Park, W., Ahn, Y.C. and Huh, S.J. (2004) Patterns of Failure in Gastric Carcinoma after D2 Gastrectomy and Chemoradiotherapy: A Radiation Oncologist’s View. British Journal of Cancer, 91, 11-17.
[19] Kim, S., Lim, K.H., Lee, J., et al. (2005) An Observational Study Suggesting Clinical Benefit for Adjuvant Ostoperative Chemoradiation in a Population of over 500 Cases after Gastric Resection with D2 Nodal Dissection for Adenocarcinoma of the Stomach. International Journal of Radiation Oncology*Biology*Physics, 63, 1279-1285.
[20] Yoo, C.H., Noh, S.H., Shin, D.W., et al. (2000) Recurrence Following Curative Resection for Gastric Carcinoma. British Journal of Surgery, 87, 236-242.
[21] Shimada, K. and Ajani, J.A. (1999) Adjuvant Therapy for Gastric Carcinoma Patients in the Past 15 Years: A Review of Western and Oriental Trials. Cancer, 86, 1657-1668.<1657::AID-CNCR6>3.0.CO;2-J
[22] Park, S.H., Kim, D.Y., Heo, J.S., Lim, D.H., Park, C.K., Lee, K.W., Choi, S.H., Sohn, T.S., Kim, S., Noh, J.H., Kim, Y.I., Park, J.O., Kim, K., Kim, W.S., Jung, C.W., Im, Y.H., Lee, M.H., Park, K., Park, C.H. and Kang, W.K. (2003) Postoperative Chemoradiotherapy for Gastric Cancer. Annals of Oncology, 14, 1373-1377.
[23] Kim, J.S., Kim, J.S., Cho, M.J., Yoon, W.H. and Song, K.S. (2006) Comparison of the Efficacy of Oral Capecitabine versus Bolus 5-FU in Preoperative Radiotherapy of Locally Advanced Rectal Cancer. Journal of Korean Medical Science, 21, 52-57.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.